CCCC Stock Overview
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
C4 Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.74 |
| 52 Week High | US$11.88 |
| 52 Week Low | US$1.06 |
| Beta | 3.19 |
| 1 Month Change | -14.68% |
| 3 Month Change | 25.51% |
| 1 Year Change | 104.86% |
| 3 Year Change | -80.34% |
| 5 Year Change | n/a |
| Change since IPO | -73.56% |
Recent News & Updates
C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched
Mar 01Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts
Feb 29
Recent updates
C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched
Mar 01Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts
Feb 29C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Feb 24New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)
Nov 03Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week
May 14C4 Therapeutics wins FDA nod to study cancer candidate in solid tumors
Sep 29C4 Therapeutics GAAP EPS of -$0.56 beats by $0.12, revenue of $13.84M beats by $5.33M
Aug 04Earnings Release: Here's Why Analysts Cut Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target To US$29.00
May 10C4 Therapeutics: Poor Data Destroyed Preclinical Promise
May 04C4 Therapeutics closes $181M capital raise
Jun 21C4 Therapeutics gets dosing underway in early-stage CFT7455 lymphoma trial
Jun 14C4 Therapeutics nears three-month high on pre-clinical data for lung cancer therapy
Jun 07Industry Analysts Just Upgraded Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Revenue Forecasts By 62%
Jun 02C4 Therapeutics to advance CFT8919 into IND-enabling studies
May 26Shareholder Returns
| CCCC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 9.2% | 4.7% | 0.7% |
| 1Y | 104.9% | 2.7% | 23.9% |
Return vs Industry: CCCC exceeded the US Biotechs industry which returned 2.9% over the past year.
Return vs Market: CCCC exceeded the US Market which returned 24.2% over the past year.
Price Volatility
| CCCC volatility | |
|---|---|
| CCCC Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CCCC's share price has been volatile over the past 3 months.
Volatility Over Time: CCCC's weekly volatility has decreased from 27% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 145 | Andrew Hirsch | www.c4therapeutics.com |
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC.
C4 Therapeutics, Inc. Fundamentals Summary
| CCCC fundamental statistics | |
|---|---|
| Market cap | US$442.42m |
| Earnings (TTM) | -US$132.49m |
| Revenue (TTM) | US$20.76m |
22.3x
P/S Ratio-3.5x
P/E RatioIs CCCC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CCCC income statement (TTM) | |
|---|---|
| Revenue | US$20.76m |
| Cost of Revenue | US$117.71m |
| Gross Profit | -US$96.95m |
| Other Expenses | US$35.54m |
| Earnings | -US$132.49m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.93 |
| Gross Margin | -467.09% |
| Net Profit Margin | -638.34% |
| Debt/Equity Ratio | 0% |
How did CCCC perform over the long term?
See historical performance and comparison